Matching articles for "Clear Eyes"
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31; 67(1725):49-56 doi:10.58347/tml.2025.1725a
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Drugs for Allergic Rhinitis and Allergic Conjunctivitis
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2021 Apr 19; 63(1622):57-64
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis
A 0.24% ophthalmic solution of the second-generation H 1 -antihistamine cetirizine ( Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic…
Med Lett Drugs Ther. 2020 Jun 1; 62(1599):81-3
A 0.24% ophthalmic solution of the second-generation H 1 -antihistamine cetirizine ( Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic conjunctivitis in patients ≥2 years old. Oral cetirizine ( Zyrtec , and others), which is used for treatment of allergic conjunctivitis and rhinitis, has been available over the counter (OTC) for years.
OTC Brimonidine (Lumify) for Ocular Redness
The FDA has approved an over-the-counter (OTC) 0.025% ophthalmic formulation of the selective alpha 2 -adrenergic agonist brimonidine tartrate ( Lumify – Bausch & Lomb) for treatment of ocular redness in…
Med Lett Drugs Ther. 2018 Oct 22; 60(1558):176
The FDA has approved an over-the-counter (OTC) 0.025% ophthalmic formulation of the selective alpha 2 -adrenergic agonist brimonidine tartrate ( Lumify – Bausch & Lomb) for treatment of ocular redness in adults and children ≥5 years old. Lumify is the first brimonidine product to be approved for OTC use.
